KNOWLEDGE HUB
Tackling Obesity
Insights on a pervasive global health challenge
Obesity is a pervasive global health challenge transcending border and, impacting millions with profound consequences to their well-being and quality of life.
Obesity prevalence could increase dramatically by 2035, to an approximately 25% of the global population classed as obese. This would mean a dramatically escalating burden on healthcare systems worldwide, fostering the rise of cardiovascular risk factors, and chronic conditions including diabetes, kidney and liver diseases. This is why there is so much interest in new obesity pharmacotherapies, with a rich pipeline of new agents, injectable and oral with a wide range of mechanisms of action from both large and emerging pharmaceutical companies.
IQVIA works with policy makers, healthcare systems, payers, pharmaceutical companies and researchers to tackle the obesity epidemic, identifying key trends, researching strategies and developing thought leadership to move forward, as well as providing solutions ranging from clinical research, real world data, market access and healthcare system capacity development, commercialisation and monitoring
2023 brought a step-change in the treatment paradigm for obesity, bringing the obesity market on the edge of a major inflection point.
Each blog of this series dives into the latest the latest trends in cardiometabolic breakthrough innovation, the market opportunity, and critical success factors for innovators, providing you with a fresh and timely perspective on the ever-changing market landscape.